Targovax, a biopharmaceutical oncology company based in Norway, recently recruited 18 patients with inoperable pancreatic cancer for the Phase I/II clinical trial of its TG01 vaccine.
The CT TG01-01 trial is testing the efficacy and safety of combining TG01 with chemotherapy to treat nonoperable pancreatic cancer.
"Recruitment of patients to Targovax’s clinical trial CT TG01-01 has been completed according to plan,” Hanne Mette Kristensen, CEO of Targovax, said. “Reaching primary endpoint for the trial was reported in November 2014, and we see this as promising for further development.”
The company will present interim results for the study during the first quarter of 2016, with final results due in the second quarter of 2017.
TG01 is a leading candidate for pancreatic cancer treatments. Targovax researchers believe it teaches the body’s immune system to detect and destroy cancer cells that show RAS mutations, one of the first signs of a normal cell becoming cancerous.
RAS mutations take place in approximately 20 percent of all cancer patients, and are frequently seen in patients with non-small cell lung cancer and colorectal cancer.
TG01 is already being used in Phase II studies with patients with operable pancreatic cancer.